Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial (vol 2, pg 691, 2014)

Ridderstrale M.; Andersen K. R.; Zeller C.; Kim G.; Woerle H. J.; Broedl U. C.

首页> 外文期刊>The lancet. Diabetes & endocrinology. >Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial (vol 2, pg 691, 2014)

【24h】

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial (vol 2, pg 691, 2014)

机译：恩帕格列净和格列美脲作为二甲双胍治疗2型糖尿病患者的比较：一项104周的随机，主动控制，双盲，3期临床试验（第2卷，第691页，2014年）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet. Diabetes & endocrinology.》 |2015年第9期|共1页
作者
Ridderstrale M.; Andersen K. R.; Zeller C.; Kim G.; Woerle H. J.; Broedl U. C.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献

1. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial (vol 2, pg 691, 2014) [J] . Ridderstrale M., Andersen K. R., Zeller C., The lancet. Diabetes & endocrinology. . 2015,第9期

机译：恩帕格列净和格列美脲作为二甲双胍治疗2型糖尿病患者的比较：一项104周的随机，主动控制，双盲，3期临床试验（第2卷，第691页，2014年）
2. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin [J] . AhrénB., JohnsonS.L., StewartM., Diabetes care . 2014,第8期

机译：和谐3：一项104周的随机，双盲，安慰剂和活性对照试验评估了阿比鲁肽与安慰剂，西他列汀和格列美脲相比在服用二甲双胍的2型糖尿病患者中的有效性和安全性
3. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control [J] . Martin Ridderstr?le, Robbyna Svaerd, Cordula Zeller, Cardiovascular Diabetology . 2013,第1期

机译：血糖控制不佳的2型糖尿病患者进行SGLT2抑制剂依帕格列净4年（208周）III期临床试验的理论，设计和基线特征，与格列美脲联用二甲双胍
4. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
5. Rationale design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin an SGLT2 inhibitor versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control [O] . Martin Ridderstråle, Robbyna Svaerd, Cordula Zeller, 2013

机译：血糖控制不佳的2型糖尿病患者进行SGLT2抑制剂依帕格列净4年（208周）III期试验的理由设计和基线特征与格列美脲联用二甲双胍
6. HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin. [O] . Ahrén, Bo, Johnson, Susan L, Stewart, Murray, 2014

机译：HaRmONY 3：104周随机，双盲，安慰剂和活性对照试验评估albiglutide与安慰剂，西他列汀和格列美脲治疗2型糖尿病患者服用二甲双胍的疗效和安全性。

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial (vol 2, pg 691, 2014)

著录项

相似文献

相关主题

期刊订阅